Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ALLO-605 + ALLO-647 + Cyclophosphamide + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALLO-605||ALLO 605|ALLO605||ALLO-605 are allogeneic T-cells engineered to express a BCMA targeting chimeric antigen receptor (CAR), with TRAC and CD52 gene inactivation, which may lead to antitumor activity (Blood (2020) 136 (Supplement 1): 8).|
|ALLO-647||ALLO 647|ALLO 647||ALLO-647 is a monoclonal antibody that targets CD52 (CAMPATH-1), which activates host immune response, potentially resulting in the lysis of CD52-positive tumor cells (NCI Drug Dictionary).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05000450||Phase Ib/II||ALLO-605 + ALLO-647 + Cyclophosphamide + Fludarabine||Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma||Recruiting||USA||0|